Preview

Кардиология

Расширенный поиск

Практические аспекты антикоагулянтной терапии дабигатраном у пациентов с фибрилляцией предсердий и АГ

https://doi.org/10.18087/cardio.2453

Полный текст:

Аннотация

Фибрилляция предсердий (ФП) является самым частым нарушением ритма сердца, ее распространенность в общей популяции составляет 1-2%, а среди лиц старше 80 лет - 15%. Артериальная гипертония (АГ) - самое частое фоновое заболевание у пациентов с ФП. В сравнении с общей популяцией риск ишемического инсульта в 3-6 раз выше у пациентов с ФП, а наличие у них АГ дополнительно увеличивает этот риск еще в 2-3 раза. Текущие клинические рекомендации требуют проведения постоянной антикоагулянтной терапии (АКТ) с целью профилактики инсульта и тромбоэмболических осложнений у большинства пациентов c подтвержденным диагнозом ФП. Неудовлетворительный контроль АД способствует не только возникновению новых случаев аритмии и ее прогрессированию, но увеличивает у пациентов риск кровотечений на фоне АКТ. В отношении пациентов с ФП при сопутствующей АГ влекущей за собой изменения со стороны органов-мишеней, должны предъявляться повышенные требования к профилю безопасности антикоагулянта. Возможность выбора в соответствии с инструкцией и рекомендациями по использованию 2 дозировок дабигатрана позволяет индивидуализировать у пациентов с ФП подход к выбору АКТ, уменьшая вероятность больших кровотечений.

Об авторах

Ж. Д. Кобалава
ФГАОУ ВО «РУДН»
Россия


А. А. Шаваров
ФГАОУ ВО «РУДН»
Россия


Список литературы

1. Barrios V, Escobar C. Risk alteration for atrial fibrillation with different antihypertensive drugs. J Atr Fibrillation. 2011;4 (4):423. DOI: 10.4022/jafib. 423

2. Miyasaka Y. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114 (2):119-25. DOI: 10.1161/CIRCULATIONAHA. 105.595140

3. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104 (11):1534-9. DOI:10.1016/j. amjcard. 2009.07.022

4. Ganapathy AV, Monjazeb S, Ganapathy KS, Shanoon F, Razavi M. “Asymptomatic” persistent or permanent atrial fibrillation: A misnomer in selected patients. Int J Cardiol. 2015;185:112-3. DOI:10.1016/j. ijcard. 2015.03.122

5. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015;128 (5):509-518. e2. DOI:10.1016/j. amj-med. 2014.11.026

6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22 (8):983-8. PMID:1866765

7. Benjamin EJ, Wolf PA, DAgostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98 (10):946-52. PMID:9737513

8. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm. 2010;7 (4):433-7. DOI:10.1016/j.hrthm. 2009.12.004

9. Benjamin EJ, Levy D, Vaziri SM, DAgostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271 (11):840-4. PMID:8114238

10. De Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen R-JS et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55 (8):725-31. DOI:10.1016/j. jacc. 2009.11.040

11. Post WS, Larson MG, Levy D. Hemodynamic predictors of incident hypertension. The Framingham Heart Study. Hypertension. 1994;24 (5):585-90. PMID:7960017

12. Сулимов В.А., Голицын С. П., Панченко Е. П., Попов С. В., Ревишвили А. Ш., Шубик Ю. В. и др. Диагностика и лечение фибрилляций предсердий. Рекомендации РКО, ВНОА И АССХ. Российский кардиологический журнал. 2013;4 S3:1-100. [Sulimov V. A., Golitsin S. P., Panchenko E. P., Popov S. V., Revishvili A. Sh., Shubik Yu. V. et al. Diagnosis and treatment of atrial fibrillation. Recommendations of RSC, RSSA and ACVS. Russ J Cardiol. 2013;4 (S3):1-100.]

13. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18 (11):1609-78. DOI:10.1093/europace/euw295

14. Blacher J, Levy BI, Mourad J-J, Safar ME, Bakris G. From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. Lancet. 2016;388 (10043):530-2. DOI:10.1016/S0140-6736 (16) 00002-7

15. Watanabe T, Kawasaki M, Tanaka R, Ono K, Nishigaki K, Takemura G et al. Association among blood pressure control in elderly patients with hypertension, left atrial structure and function and new-onset atrial fibrillation: a prospective 2-year study in 234 patients. Hypertens Res. 2013;36 (9):799-806. DOI:10.1038/hr. 2013.25

16. Barrios V, Escobar C, Echarri R. Atrial Fibrillation And Coronary Heart Disease: Fatal Attraction. J Atr Fibrillation. 2009;1 (5):137. DOI:10.4022/jafib. 137

17. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart Disease and Stroke Statistics - 2016 Update: A Report From the American Heart Association. Circulation. 2016;133 (4) :e38-360. DOI: 10.1161 /CIR. 0000000000000350

18. Cifkova R, Fodor G, Wohlfahrt P. Changes in hypertension prevalence, awareness, treatment, and control in High-, Middle-, and Low-income countries: an update. Curr Hypertens Rep. 2016;18 (8):62. DOI: 10.1007/s11906-016-0669-y

19. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386 (9989): 154-62. D0I:10.1016/S0140-6736 (14) 61774-8

20. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129 (8):837 47. D0I:10.1161 / CIRCULATIONAHA. 113.005119

21. Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34 (35) :2746-51. DOI: 10.1093/eurheartj /eht280

22. Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The Epidemiology ofAtrial Fibrillation and Stroke. Cardiol Clin. 2016;34 (2):255-68. DOI:10.1016/j. ccl. 2015.12.002

23. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285 (18):2370-5. PMID:11343485

24. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost. 2013; 110 (2) :213-22. DOI: 10.1160/TH13-02-0165

25. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111 (6):1167-76. DOI: 10.1160/TH14-03-0231

26. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener H-C, Bernstein RA et al. Uncovering atrial fibrillation beyond shortterm monitoring in cryptogenic stroke patients: three-year results from the cryptogenic stroke and underlying atrial fibrillation trial. Circ Arrhythm Electrophysiol. 2016;9 (1):e003333. DOI:10.1161 /CIRCEP. 115.003333

27. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363 (19):1875-6. DOI:10.1056/NEJMc1007378

28. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152 (1):86-92. PMID:16838426

29. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356 (9244): 1789-94. PMID:11117910

30. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126 (2):476-86. DOI:10.1378/chest. 126.2.476

31. BassandJ-P, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KAA et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European HeartJournal. 2016;37 (38):2882-9.DOI:10.1093/eurheartj/ehw233

32. Лукьянов М. М., Бойцов С. А., Якушин С. С., Марцевич С. Ю., Воробьев А. Н., Загребельный А. В. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА). Рациональная Фармакотерапия В Кардиологии. 2014;10 (4):366-77. [Loukianov M. M., Boytsov S. A., Yakushin S. S. et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of “atrial fibrillation” in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Ration Pharmacother Cardiol 2014;10 (4):366-377.]

33. Guo Y, Wang H, Tian Y, Wang Y, Lip GYH. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke. Thromb Haemost. 2016;115 (1):184-92. DOI: 10.1160/TH 15-07-0577

34. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33 (12):1500-10. DOI:10.1093/eurheartj/ehr488

35. Arima H, Hart RG, Colman S, Chalmers J, Anderson C, Rodgers A et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2005;36 (10):2164-9. DOI:10.1161/01. STR. 0000181115.59173.42

36. Sagie A, Benjamin EJ, Galderisi M, Larson MG, Evans JC, Fuller DL et al. Echocardiographic assessment of left ventricular structure and diastolic filling in elderly subjects with borderline isolated systolic hypertension (the Framingham Heart Study). Am J Cardiol. 1993;72 (9):662-5. PMID:8249841

37. Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol. 1997;80 (12):1566-71. PMID:9416937

38. Kishima H, Mine T, Kodani T, Masuyama T. Prediction of left atrial thrombi in patients with atrial tachyarrhythmias during warfarin administration: retrospective study in Hyogo College of Medicine. Heart Vessels. 2015;30 (3):331-7. DOI:10.1007/s00380-014-0496-5

39. Kimura M, Wasaki Y, Ogawa H, Nakatsuka M, Wakeyama T, Iwami T et al. Effect of low-intensity warfarin therapy on left atrial thrombus resolution in patients with nonvalvular atrial fibrillation: a transesophageal echocardiographic study. Jpn Circ J. 2001;65 (4):271-4. PMID:11316121

40. Boyd AC, McKay T, Nasibi S, Richards DAB, Thomas L. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. European Heart Journal - Cardiovascular Imaging. 2013;14 (3):269-75. DOI:10.1093/ehjci/jes153

41. Paciaroni M, Agnelli G, Ageno W, Caso V. Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation. Thromb Haemost. 2016;116 (3):410-6. DOI: 10.1160/TH16-03-0217

42. Lip GYH, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost. 2016;14 (9):1711-4. DOI:10.1111/jth. 13386

43. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285 (22):2864-70. PMID:11401607

44. Senoo K, Proietti M, Lane DA, Lip GYH. Evaluation of the HASBLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. Am J Med. 2016;129 (6):600-7. DOI:10.1016/j. amjmed. 2015.10.001

45. Hijazi Z, OldgrenJ, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW et al. The novel biomarker-based ABC (age, biomarkers, clinical history) - bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387 (10035):2302-11. DOI:10.1016/S0140-6736 (16) 00741-8

46. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376 (9735):112-23. DOI:10.1016/S0140-6736 (10) 60834-3

47. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30 (6):1223-9. PMID:10356104

48. Lip GYH, Frison L, Grind M, SPORTIF Invetigators. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28 (6):752-9. DOI:10.1093/eurheartj/ehl504

49. HealeyJS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. 2008;39 (5): 1482-6. DOI: 10.1161 /STROKEAHA. 107.500199

50. Kodani E, Atarashi H, Inoue H, Okumura K, Yamashita T, Otsuka T et al. Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. J Am Heart Assoc. 2016;5 (9).DOI:10.1161/JAHA. 116.004075

51. Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol. 2015;116 (8):1204-9. DOI:10.1016/j. amjcard. 2015.07.032

52. Rao MP, Halvorsen S, Wojdyla D, Thomas L, AlexanderJH, Hylek EM et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: rfsults From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. J Am Heart Assoc. 2015;4 (12). DOI:10.1161/JAHA. 115.002015

53. Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc. 2002;94 (8 Suppl): 7S - 15S. PMID:12152917

54. Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5 (2):173-81. DOI:10.2215/CJN. 03170509

55. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electro-physiol. 2011;4 (1):26-32. DOI:10.1161/CIRCEP. 110.957100

56. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. AmJ Med. 2007;120 (8):700-5. DOI:10.1016/j. amjmed. 2006.07.034

57. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164 (8):880-4. DOI:10.1001 /archinte. 164.8.880

58. Dixon AA, Holness RO, Howes WJ, Garner JB. Spontaneous intracerebral haemorrhage: an analysis of factors affecting prognosis. Can J Neurol Sci. 1985;12 (3):267-71. PMID:4052889

59. BroderickJP, Adams HP, Barsan W, Feinberg W, Feldmann E, GrottaJ et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30 (4):905-15. PMID:10187901

60. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344 (19): 1450-60. DOI: 10.1056/NEJM200105103441907

61. Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63 (6):1059-64. PMID:15452298

62. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133 (6 Suppl): 257S - 298S. DOI: 10.1378/chest. 08-0674

63. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68 (2):116-21. DOI:10.1212/01. wnl. 0000250340.05202.8b

64. Lee SB, Manno EM, Layton KF, Wijdicks EFM. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006;67 (7):1272-4. DOI:10.1212/01. wnl. 0000238104.75563.2f

65. Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J et al. Hematoma growth and outcome in treated neurocriti-cal care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37 (6):1465-70. DOI:10.1161/01. STR. 0000221786.81354. d6

66. Sjöblom L, Hardemark HG, Lindgren A, Norrving B, Fahlen M, Samuelsson M et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke. 2001;32 (11):2567-74. PMID:11692018

67. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118 (3):321-33. DOI:10.1016/j. thromres. 2005.08.007

68. Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res. 2006;117 (5):493-9. DOI:10.1016/j. thromres. 2004.11.025

69. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44 (11):3103-8. DOI:10.1161 /STROKEAHA. 113.002329

70. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007;147 (8):590-2. PMID:17938402

71. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110 (6):1087-107. D OI: 10.1160/TH13-06-0443

72. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123 (7):638-645. e4. DOI:10.1016/j. amjmed. 2009.11.025

73. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365 (10):883-91. DOI: 10.1056/NEJMoa1009638

74. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365 (11):981-92. D OI: 10.1056/NEJMoa1107039

75. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369 (22):2093-104. DOI:10.1056/ NEJMoa1310907

76. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361 (12):1139-51. DOI:10.1056/NEJMoa0905561

77. EikelboomJW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013;62 (10):900-8. DOI:10.1016/j. jacc. 2013.05.042

78. Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueck-mann M et al. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation-the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2017; DOI:10.1093/europace/eux022

79. Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA et al. Changes in renal function in patients with atrial fibrillation. Journal of the American College of Cardiology. 2015;65 (23):2481-93. DOI:10.1016/j. jacc. 2015.03.577

80. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term anticoagulation therapy) trial analysis. Circulation. 2014; 129 (9):961-70. DOI: 10.1161 /CIRCULATIONAHA. 113.003628

81. Lip GYH, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014;111 (5):933-42. DOI: 10.1160/TH13-09-0734

82. Larsen TB, Rasmussen LH, Skj0th F, Due KM, Callreus T, Rosenzweig M et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61 (22):2264-73. DOI:10.1016/j. jacc. 2013.03.020

83. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131 (2):157-64. DOI:10.1161 /CIRCULATIONAHA. 114.012061

84. Graham DJ, Reichman ME, Wernecke M, Hsueh Y-H, Izem R, Southworth MR et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for non-valvular atrial fibrillation. JAMA Intern Med. 2016;176 (11):1662-71. DOI:10.1001 /jamainternmed. 2016.5954

85. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-World setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48 (9):2494-503. DOI:10.1161/STROKEAHA. 117.017549

86. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal. 2011;32 (19):2387-94. DOI:10.1093/eurheartj/ehr342

87. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28 (10):973-7. PMID:570666

88. Tohgi H, Tajima T, Konno T, Towada S, Kamata A, Yamazaki M. The risk of cerebral infarction in non-valvular atrial fibrillation: effects of age, hypertension and antihypertensive treatment. Eur Neurol. 1991;31 (3):126-30. PMID :2044624

89. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J. 2000;139 (5):814-9. PMID:10783214

90. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992;116 (1):6-12. PMID:1727097

91. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154 (13):1449-57. PMID:8018000

92. Authors/Task Force Members, Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension ofthe European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal. 2013;34 (28):2159-219.DOI:10.1093/eurheartj/eht151

93. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356 (9246):1955-64. PMID:11130523

94. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant. 1998;13 (3):564-9. PMID:9550628

95. Gottdiener JS, Reda DJ, Williams DW, Materson BJ, Cushman W, Anderson RJ. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation. 1998;98 (2):140-8. PMID:9679720

96. Hughes M, Lip GYH, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007; 100 (10):599-607. DOI:10.1093/qjmed/hcm076

97. Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 survey of atrial fibrillation and stroke: Gaps in knowledge and perspective, opportunities for improvement. Heart Rhythm. 2015; 12 (8):e105-113. DOI:10.1016/j. hrthm. 2015.04.039

98. O’Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167 (4):601-609. e1. DOI:10.1016/j. ahj. 2013.12.014

99. Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125 (8):773-8. DOI:10.1016/j. amjmed. 2012.01.033

100. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159 (7):677-85. PMID:10218746

101. MantJ, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370 (9586):493-503. DOI:10.1016/S0140-6736 (07) 61233-1

102. Diener H-C, EikelboomJ, Connolly SJ, Joyner CD, Hart RG, Lip GYH et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11 (3):225-31. DOI:10.1016/S1474-4422 (12) 70017-0

103. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119 (10):1363-9. DOI:10.1161 /CIRCULATIONAHA. 108.816082

104. Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney International. 2011;80 (2):181-9. DOI:10.1038/ki.2011.44

105. Amara W, Larsen TB, Sciaraffia E, Hernandez Madrid A, Chen J, Estner H et al. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. Europace. 2016;18 (1):151-5. DOI:10.1093/europace/euv317

106. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125 (5):669-76. DOI: 10.1161/CIRCULATIONAHA. 111.055970

107. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122 (22):2246-53.DOI:10.1161/CIRCULATIONAHA. 110.973735


Для цитирования:


Кобалава Ж.Д., Шаваров А.А. Практические аспекты антикоагулянтной терапии дабигатраном у пациентов с фибрилляцией предсердий и АГ. Кардиология. 2018;58(1S):42-55. https://doi.org/10.18087/cardio.2453

For citation:


Kobalava Z.D., Shavarov A.A. Practical aspects of anticoagulant therapy in patients with atrial fibrillation and arterial hypertension. Kardiologiia. 2018;58(1S):42-55. (In Russ.) https://doi.org/10.18087/cardio.2453

Просмотров: 103


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)